Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics

  • ID: 2759700
  • Report
  • 32 Pages
  • La Merie Publishing
1 of 5
Novel Prophylactic and Therapeutic Approaches to Manage and Prevent Clostridium difficile Infections (CDI)

FEATURED COMPANIES

  • Actelion
  • AstraZeneca (MedImmune)
  • Cubist Pharmaceuticals
  • Novacta Therapeutics
  • Rebiotix
  • Stellar Biotechnologies
  • MORE
Clostridium difficile infections (CDI) are a major public health concern. CDI are becoming increasingly prevalent in hospitals, long-term and primary-care facilities, primarily in patients whose normal intestinal flora have been compromised by antibiotic treatment. CDI primary virulence mechanismis the production of two toxins, TcdA and TcdB, which glucosylate Rho-family GTPases, disrupt the actin cytoskeleton, and causing cytotoxicity and inflammation.

The present Competitive Intelligence Report about prophylaxis and therapy of Clostridium difficile infections provides a competitor evaluation in the field of new molecules or microorganisms for prevention or treatment of Clostridium difficle infections as of January 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in research and development of antibodies, proteins, peptides, vaccines, microorganisms and small molecules for prevention and treatment of Clostridium difficile infections. In addition, the report lists company-specific R&D pipelines of C. difficile vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on:

- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Actelion
  • AstraZeneca (MedImmune)
  • Cubist Pharmaceuticals
  • Novacta Therapeutics
  • Rebiotix
  • Stellar Biotechnologies
  • MORE
- C. difficile Vaccines
- C. difficile Antibodies
- C. difficile Antibiotics
- C. difficile targeting Microorganisms
- C. difficile Anti-Infectives
- Corporate C. difficile Vaccines & Therapeutics R&D Pipelines
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
- Actelion
- AIMM Therapeutics
- AmpliPhi Biosciences
- Astellas Pharma
- AstraZeneca (MedImmune)
- Aviex Technologies
- Biota Pharmaceuticals
- Crestone
- Cubist Pharmaceuticals
- DaVolterra
- Immuron
- Merck
- Novacta Therapeutics
- Novartis
- Pfizer
- Prokarium
- Rebiotix
- Sanofi Pasteur
- Seres Health
- Shire (ViroPharma)
- Stellar Biotechnologies
- Summit
- Synthetic Biologics
- Valneva
- VaxInnate
- Venenum Biodesign
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll